Opthea Wet AMD Program to be Presented at Innovate Retina
Opthea (ASX/NASDAQ: OPT) announced that its wet age-related macular degeneration (wet AMD) program will be presented at the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. Dr. David Boyer will provide an update on sozinibercept, highlighting:
- The unmet medical need in wet AMD
- Phase 2b trial results
- Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy
The presentation, titled 'Update on OPT-302 (sozinibercept)', is scheduled for 5:27 PM CT during Session 4: New Routes and New Molecules. Innovate Retina focuses on innovations in retina care, including AMD management, ocular imaging, gene therapy, and advances in retinal pharmacotherapy.
Opthea (ASX/NASDAQ: OPT) ha annunciato che il suo programma per la degenerazione maculare legata all'età umida (wet AMD) sarà presentato all'Innovate Retina Meeting il 17 ottobre 2024 a Chicago, Illinois. Il Dr. David Boyer fornirà un aggiornamento su sozinibercept, evidenziando:
- Il bisogno medico non soddisfatto nella wet AMD
- I risultati della sperimentazione di fase 2b
- Il programma di fase 3 progettato per valutare la superiorità nella acuità visiva della terapia combinata con sozinibercept rispetto alla monoterapia anti-VEGF-A
La presentazione, intitolata 'Aggiornamento su OPT-302 (sozinibercept)', è programmata per le 17:27 CT durante la Sessione 4: Nuove vie e nuove molecole. Innovate Retina si concentra sulle innovazioni nella cura della retina, inclusa la gestione della AMD, l'imaging oculare, la terapia genica e i progressi nella farmacoterapia retinica.
Opthea (ASX/NASDAQ: OPT) anunció que su programa para la degeneración macular húmeda relacionada con la edad (wet AMD) será presentado en la Innovate Retina Meeting el 17 de octubre de 2024 en Chicago, Illinois. El Dr. David Boyer proporcionará una actualización sobre sozinibercept, destacando:
- La necesidad médica no satisfecha en wet AMD
- Resultados del ensayo de fase 2b
- El programa de fase 3 diseñado para evaluar la superioridad en agudeza visual de la terapia combinada con sozinibercept sobre la monoterapia anti-VEGF-A
La presentación, titulada 'Actualización sobre OPT-302 (sozinibercept)', está programada para las 5:27 PM CT durante la Sesión 4: Nuevas Rutas y Nuevas Moléculas. Innovate Retina se centra en innovaciones en el cuidado de la retina, incluida la gestión de la AMD, la imagenología ocular, la terapia génica y los avances en la farmacoterapia retiniana.
Opthea (ASX/NASDAQ: OPT)는 습성 노인성 황반변성(wet AMD) 프로그램이 2024년 10월 17일 일리노이주 시카고에서 열리는 Innovate Retina Meeting에서 발표될 것이라고 발표했습니다. David Boyer 박사는 sozinibercept에 대한 업데이트를 제공하며 다음을 강조합니다:
- 습성 AMD에서의 충족되지 않은 의료 필요
- 2b상 시험 결과
- sozinibercept와의 병용 요법이 anti-VEGF-A 단독 요법에 비해 시력 향상에서 우월성을 평가하도록 설계된 3상 프로그램
'OPT-302 (sozinibercept)에 대한 업데이트'라는 제목의 발표는 세션 4: 새로운 경로와 새로운 분자 동안 오후 5:27 CT로 예정되어 있습니다. Innovate Retina는 AMD 관리, 안구 이미징, 유전자 요법 및 망막 약물 치료의 발전을 포함한 망막 치료의 혁신에 중점을 둡니다.
Opthea (ASX/NASDAQ: OPT) a annoncé que son programme de dégénérescence maculaire liée à l'âge humide (wet AMD) sera présenté lors de la réunion Innovate Retina le 17 octobre 2024 à Chicago, Illinois. Le Dr. David Boyer donnera une mise à jour sur sozinibercept, en mettant en avant :
- Le besoin médical non satisfait dans la wet AMD
- Les résultats de l'essai de phase 2b
- Le programme de phase 3 conçu pour évaluer la supériorité en acuité visuelle de la thérapie combinée avec sozinibercept par rapport à la monothérapie anti-VEGF-A
La présentation, intitulée 'Mise à jour sur OPT-302 (sozinibercept)', est prévue pour 17h27 CT lors de la session 4 : Nouvelles voies et nouvelles molécules. Innovate Retina se concentre sur les innovations dans le soin de la rétine, y compris la gestion de la AMD, l'imagerie oculaire, la thérapie génique et les avancées en pharmacothérapie rétinienne.
Opthea (ASX/NASDAQ: OPT) gab bekannt, dass das Programm zur feuchten altersbedingten Makuladegeneration (wet AMD) auf dem Innovate Retina Meeting am 17. Oktober 2024 in Chicago, Illinois, präsentiert wird. Dr. David Boyer wird ein Update zu sozinibercept geben und Folgendes hervorheben:
- Den ungedeckten medizinischen Bedarf bei feuchter AMD
- Ergebnisse der Phase 2b-Studie
- Das Phase 3-Programm, das darauf abzielt, die Überlegenheit der Kombinationstherapie mit sozinibercept gegenüber der Anti-VEGF-A Monotherapie in Bezug auf die Sehschärfe zu bewerten
Die Präsentation mit dem Titel 'Update zu OPT-302 (sozinibercept)' ist für 17:27 Uhr CT während Sitzung 4: Neue Wege und neue Moleküle geplant. Innovate Retina konzentriert sich auf Innovationen in der Netzhautpflege, einschließlich AMD-Management, Augenbildgebung, Gentherapie und Fortschritten in der retinalen Pharmakotherapie.
- Presentation of sozinibercept at a prominent retina innovation meeting
- Opportunity to showcase Phase 2b trial results and Phase 3 program design
- Potential to address unmet medical needs in wet AMD treatment
- None.
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois.
David Boyer, MD, will present an update on Opthea’s wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy.
Details are as follows:
Session 4: New Routes and New Molecules
Timing: Thursday, October 17, 2024, 5:27 PM CT
Presentation: Update on OPT-302 (sozinibercept)
Presenter: David S. Boyer, MD
Agenda: https://retinainnovate.com/agenda/
Innovate Retina focuses exclusively on game-changing innovations in medical and surgical retina care, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology, and the latest advances in retinal pharmacotherapy.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pjkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When and where will Opthea's wet AMD program be presented?
Who will be presenting Opthea's (OPT) sozinibercept update?
What will be included in Opthea's (OPT) presentation at Innovate Retina?
What is the focus of the Innovate Retina meeting where Opthea (OPT) will present?
